QuickView: Entering a newsflow-rich period
Cerulean looks well positioned to progress its ripening pipeline after a recent successful share offer and the receipt of FDA fast track designation for lead compound CRLX101. We see multiple potential share price catalysts this year on updated trials for CRLX101 in renal (RCC), ovarian and non-metastatic rectal cancer, as well as first data coming through for CRLX301 in solid tumours. Q115 results on 6 May confirmed that its broadening clinical programme remains on track.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.